Laura Curti

Post Doc

Research Lines

Genomic Science






2016  Ph.D in Pharmaceutical Sciences at University of Geneva, Switzerland.

2010  Master Degree in Applied Biology to Biomedical Research at Insubria University, Varese, Italy.

2007  Bachelor Degree in Medical Biology at Insubria University, Varese, Itay.


Professional Experience

November 2016 – present:           Post-doc, Cancer Biology group, Center for Genomic Science at IIT@SEMM, Milan, Italy.

January 2012 – April 2016:           PhD student, Doctoral program in Pharmaceutical Sciences,

                                                        Prostate Cancer Biology group at Institute of Oncology Research (IOR), Bellinzona, Switzerland.

April 2010 – December 2011:       Biologist, Prostate Cancer Biology group at Institute of Oncology Research (IOR), Bellinzona, Switzerland.

Februry 2009 – April 2010:           Visiting StudentProstate Cancer Biology group at Institute of Oncology Research (IOR), Bellinzona, Switzerland.

March 2007 – September 2007:   Visiting Student, Laboratory of General Pathology at Insubria University of Varese, Busto Arsizio, Italy.    

Selected Publications

Croci O., De Fazio S.,Biagioni F.,Donato E., Caganova M., Curti L., Doni M.Sberna S.Aldeghi D.Biancotto C., Verrecchia A.Olivero D.Amati B. and Campaner S. Transcriptional integration of mitogenic and mechanical signals by Myc and YAP (2017). Genes & Development, 31:2017-2022.

Albino D., Civenni G., Dallavalle C., Roos M., Jahns H., Curti L., Rossi S., Pinton S., D'Ambrosio G., Sessa F., Hall J., Catapano CV, Carbone GM. Activation of the Lin28/let-7 Axis by Loss of ESE3/EHF Promotes a Tumorigenic and Stem-like Phenotype in Prostate Cancer (2016). Cancer Research, 76(12):3629-43.

Albino D., Longoni N., Curti L., Mello-Grand M., Pinton S., Civenni G., Thalmann G., D’Ambrosio G., Sarti M., Sessa F., Chiorino G., Catapano CV. and Carbone GM. ESE3/EHF Controls Epithelial Cell Differentiation and Its Loss Leads to Prostate Tumors with Mesenchymal and Stem-like Features (2012). Cancer Research, 72(11):2889-900.

Curti L., Babbio F., Pistore C., Kunderfranco P., Brino L., Oudet P., Seiler R., Thalman GN., Roggero E., Sarti M., Pinton S., Mello-Grand M., Chiorino G., Catapano CV., Carbone GM and Bonapace IM. The SRA protein UHRF1 promotes epigenetic cross-talk and is involved in prostate cancer progression (2012). Oncogene, 31(46):4878-87.